New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non - small cell lung cancer: Comparison with original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

American Journal of Roentgenology

Volumn 195, Issue 3, 2010, Pages

  Nishino, Mizuki ^a   Jackman, David M ^b   Hatabu, Hiroto ^b   Yeap, Beow Y ^c   Cioffredi, Leigh Anne ^b   Yap, Jeffrey T ^a   Jänne, Pasi A ^b   Johnson, Bruce E ^b   Van Den Abbeele, Annick D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CT; Lung cancer; PET CT; Response Evaluation Criteria in Solid Tumors (RECIST); Tumor measurement

Indexed keywords

ERLOTINIB; IOPROMIDE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR GUIDELINE 1.0; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR GUIDELINE 1.1; RETROSPECTIVE STUDY; STUDENT T TEST; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED TOMOGRAPHY; LUNG NEOPLASMS; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77956862485     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.09.3928     Document Type: Article

References (19)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
3. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 2008; 28:329-344
4. Bogaerts J, Ford R, Sargent D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 2009; 45:248-260
5. Moskowitz CS, Jia X, Schwartz LH, Gönen M. A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 2009; 45:300-310
6. Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009; 45:261-267
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
9. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13,306-13,311
11. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73
12. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043
13. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-792 (Pubitemid 40271173)
14. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-766
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310 (Pubitemid 16134762)
17. Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with nonsmall cell lung cancer. Radiology 2009; 252:263-272
18. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003; 228:303-308
19. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21:2574-2582